• Krystal Biotech updated full-year 2026 non-GAAP research and development and selling, general and administrative expense guidance to $155 million–$165 million.
• Third-quarter net product revenue reached $127.3 million, compared with $97.8 million a year earlier.
• Net income fell to $63.1 million from $79.4 million a year earlier.
• A $400 million share repurchase program is being initiated; cash and investments totaled $1.2 billion as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.